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Abstract: Increased angiogenesis is associated with a higher metastasis- and mortality rate in uveal
melanoma (UM). Recently, it was demonstrated that genetic events, such as 8q-gain and BAP1-loss,
influence the level of immune infiltrate. We aimed to determine whether genetic events, and specific
cytokines, relate to angiogenesis in UM. Data from UM patients who underwent enucleation between
1999 and 2008 were analysed. Microvascular density (MVD) and the presence of infiltrating immune
cells were determined with immunohistochemistry (IHC) and immunofluorescence in 43 cases.
Chromosome status, BAP1 IHC and mRNA expression of angiogenesis-related genes were known
in 54 cases. Tumours with monosomy 3/BAP1-loss showed a higher MVD compared to tumours
with disomy 3/normal BAP1 expression (p = 0.008 and p = 0.004, respectively). Within BAP1-positive
lesions (n = 20), 8q-gain did not relate to MVD (p = 0.51). A high MVD was associated with an
increased expression of angiopoietin 2 (ANGPT2) (p = 0.041), Von Willebrand Factor (VWF) (p = 0.010),
a decreased expression of vascular endothelial growth factor B (VEGF-B) (p = 0.024), and increased
numbers of tumour-infiltrating macrophages (CD68+, p = 0.017; CD68+CD163+, p = 0.031) and
lymphocytes (CD4+, p = 0.027). Concluding, vascular density of UM relates to its genetic profile:
Monosomy 3 and BAP1-loss are associated with an increased MVD, while an early event (gain of 8q)
is not independently related to MVD, but may initiate a preparation phase towards development of
vessels. Interestingly, VEGF-B expression is decreased in UM with a high MVD.
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1. Introduction
Uveal melanoma (UM) is the most common ocular malignancy in Caucasian adults. The disease is
often lethal with up to 50% of patients developing metastases [1]. In recent years, research has focussed
on targeted and immunotherapeutic therapies, as promising results were obtained in the treatment of,
for example, cutaneous melanoma. Results in UM are disappointing; however, and questions remain
regarding the mechanisms leading to metastases and the tumour’s resistance to treatment. We sought
to learn more about the relation between the tumour’s immunological microenvironment and the
development of angiogenesis, which is an important parameter in growth and behaviour of UM, and a
potential target for therapy.
Restricted by the limits of diffusion (1–2 mm), an expanding UM requires new vessels to grow.
The concept of the “angiogenic switch” describes the turning point between an initial phase of slow,
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avascular growth into a phase with more rapid growth and angiogenesis. Angiogenesis can be studied
using micro-vascular density (MVD). An increased MVD has been associated with a higher metastasis
rate [2] and mortality rate in UM [3,4]. Since UM metastasizes solely via the haematogenous route,
it is logical to assume a relation between growth of intra-tumoural vessels and systemic spread.
This concept led to the hypothesis that anti-angiogenic therapy could be used to treat UM or its
metastases. One recent study reports a potential benefit of treatment with anti- vascular endothelial
growth factor (VEGF) therapy in metastatic UM [5], but others stress that anti-angiogenic therapy
has been unsuccessful in UM [6]. This illustrates that there are still questions to be answered to fully
understand angiogenesis in UM. Scientific interest in tumour vascularization has recently increased as
new targets, including hypoxia signalling [7], have proven to be promising in the therapeutic approach
of UM [8].
While angiogenesis describes the formation of endothelial-lined new vessels, it is important to
note that other mechanisms resulting in intra-tumoural vascular channels have been recognized in
UM [9,10]. This phenomenon is called “vascular mimicry”, and can be depicted by periodic acid–Schiff
(PAS) staining of extravascular matrix patterns. The presence of so-called loops and networks in UM
was related to the MVD [11] and worse prognosis [11]. However, the exact function and development
of these channels remains debated.
The MVD of UM is known to be associated with the tumour’s immune infiltrate. Studies on this
topic have focussed mainly on the relation with an increased presence of macrophages, describing
their pro-angiogenic properties. An association between a higher MVD and increased numbers of
all macrophages (CD68+ cells) [12] and M2 type macrophages (CD68+CD163+ cells) [2] has been
established. Recently, it was found that genetic changes that reflect the evolution of UM relate to
the type of immune infiltrate in tumour samples [13]. Gain of chromosome 8q (an early event in
UM development [14,15]) is related to an increased presence of macrophages, while the loss of BAP1
expression (a later event) is related to an increased presence of T cells. Currently, the roles of 8q gain
or BAP1 loss in angiogenesis are unknown. As monosomy 3 and BAP1 loss are very important for
prognosis in this disease [16,17], and they play a role in developing an inflammatory phenotype [18],
we wondered if angiogenesis as demonstrated by MVD is similarly regulated by these genetic events.
We hypothesize that genetic changes not only influence the immunological microenvironment,
but also drive angiogenesis in UM, and that MVD is a consequence of a highly-malignant genetic
profile. We set out to test this, and also analysed if several angiogenesis-related cytokines are expressed
in relation to the development of tumour vascularity of primary UM.
2. Results
2.1. A High MVD Relates to a Mixed/Epithelioid Cell Type and a Worse Clinical Outcome
As a high MVD is known to be associated with a bad prognosis in UM, we first determined
whether our population confirmed the existing assumptions. The MVD had been determined by
counting CD34-expressing vessels in sections of 43 UM, using a well-established technique as presented
by Makitie et al. [3]. The mean age at enucleation of these patients was 60.6 years. The median largest
basal diameter (LBD) of the tumours was 13.0 mm. Following the American Joint Committee on Cancer
(AJCC) tumour-node-metastasis (TNM) staging criteria, three (7%) tumours were Stage T1, 22 (51%)
Stage T2 and 18 (42%) Stage T3. Further details on the patient and tumour characteristics are provided
in Table 1.
The median MVD count was 89.0 CD34+ vessels/mm2 (Range: 28.0–202.0). A high MVD was
related to a mixed/epithelioid cell type (p = 0.004), but not to gender (p = 0.89), age (p = 0.25), tumour
stage (p = 0.23) or tumour pigmentation (p = 0.45). When looking at a comparison with vascular
mimicry, the median MVD count increased from cases without loops or networks (71.0 vessels/mm2), to
those with loops only (83.0 vessels/mm2) and those with both loops and networks (102.0 vessels/mm2)
(p = 0.052). The median follow-up time was 120 months (range: 14–205 months). In total, 18 patients
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(42%) developed metastasis and died of melanoma-related causes. A high MVD was related to the
development of metastasis (p = 0.009) and the occurrence of metastasis-related death (p = 0.009)
(Table 1), similarly presented in Figure 1a.
Table 1. Patient and tumour characteristics of 43 uveal melanoma patients for whom data on micro-vascular
density (MVD) were available.
Categorical
Total MVD
p-Value
Cases (%) Median
Gender
Male 23 (53) 89.0 0.85 #
Female 20 (47) 88.5
Side
OD 23 (53) 86.0 0.95 #
OS 20 (47) 93.5
TNM stage (8th)
T1 4 (9) 79.0 0.23 *
T2 14 (33) 82.0
T3 25 (58) 91.0
Pigmentation
Light 29 (67) 89.0 0.97 #
Dark 14 (33) 96.5
Cell Type
Spindle 11 (26) 69.0 0.009 #
Mixed + Epithelioid 32 (74) 100.0
Ciliary Body
Involvement
No 24 (56) 89.0 0.58 #
Yes 19 (44) 103.0
Loops and Networks
None 7 (16) 71.0 0.052 *
Loops+, networks− 8 (19) 83.0
Loops+, networks+ 27 (63) 102.0
Metastasis
No 25 (58) 76.0 0.010 #
Yes 18 (42) 110.0
Melanoma-Related
Death
No 25 (58) 76.0 0.010 #
Yes 18 (42) 110.0
NUMERICAL Total
Correlation p-Value
Spearman
Age—Median 63.6 0.135 0.390
LBD—Median 13.0 0.299 0.051
Prominence—Median 8.0 −0.278 0.072
p values were calculated with: # Mann–Whitney U test, * Jonckheere test for trend. (Abbreviations: TNM,
tumour-node-metastasis; LBD, largest basal diameter).
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2.2. MVD Relates to the Expression of Several Angiogenesis-Related Genes
To identify the relevance of angiogenesis-related pathways in UM, we related the MVD to the
mRNA expression levels of several selected angiogenesis-related genes. Data on MVD as well as
mRNA expression was available for 28 UM patients. Potentially-relevant genes were selected from
the literature because of their theoretical role in angiogenesis, such as those coding for VEGF-A/B/C,
HIF1a, ANGPT1/2, and PDGF-A. We also analysed vessel markers such as CD34 and PECAM1 (CD31).
Patient and tumour characteristics of the 28 patients are provided in Table S1.
A high MVD (defined as number of CD34+ vessels/mm2) was correlated with an increased
mRNA expression of the vessel markers CD34 (p = 0.007) and PECAM1 (p = 0.055), the pro-angiogenic
factors ANGPT2 (p = 0.041) and VWF (p = 0.010), and a decreased expression of VEGF-B (p = 0.024).
The expression of VEGF-A was not related to MVD (p = 0.98), while the expression of HIF1a (p = 0.089)
and CDH1 (p = 0.079) demonstrated a trend towards an increase with a higher MVD, but this did not
reach statistical significance (Table 2). A low expression of VEGF-B (but not VEGF-A) was related to
worse survival in a Kaplan–Meier analysis (Figure 1c,d).
2.3. MVD Relates to Increased Numbers of Macrophages (CD68+) as Well as T Cells (CD4+)
Previously, MVD was found to correlate with the number of tumour-infiltrating macrophages [2].
This was confirmed in the current set of 43 tumours, by determining the numbers of lymphocytes
(CD3+, CD4+, CD8+, FoxP3+; using immunofluorescence (IF) [19]) and macrophages (CD68+, CD163+,
CD68+CD163+; using IF [2]). A higher MVD was significantly associated with an increased number of
CD68+ (r 0.361, p = 0.017), and CD68+CD163+ (r 0.329, p = 0.031) macrophages, and also with the
number of CD4+ (r 0.336, p = 0.027) T cells. A trend was observed between a high MVD and increased
counts of CD3+ (r 0.287, p = 0.062), CD8+ (r 0.271, p = 0.062) and FoxP3+ (r 0.283, p = 0.078) cells.
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Table 2. mRNA expression of angiogenesis-related genes in relation to MVD (n = 28).
mRNA Median (Range) Spearman Corr. p-Value
VEGF-A 6.76 (6.51–7.34) 0.005 0.989
VEGF-B 8.54 (7.6–9.41) −0.425 0.024 *
VEGF-C 6.73 (6.37–7.73) 0.209 0.286
HIF1A 7.21 (6.89–7.91) 0.327 0.089
VHL 7.96 (7.35–8.54) −0.226 0.248
ANGPT1 6.57 (6.31–7.04) 0.155 0.431
ANGPT2 6.54 (6.23–8.19) 0.389 0.041 *
PDGFA 6.96 (6.46–7.82) 0.060 0.761
CD34 7.37 (6.73–7.9) 0.497 0.007 *
CDH1 10.74 (5.8–12.94) 0.337 0.079
PECAM1 7.23 (6.68–9.57) 0.367 0.055
VWF 9.86 (8.62–11.14) 0.479 0.010 *
* p-value < 0.05.
2.4. MVD Relates to Monosomy 3 and BAP1 Loss, but Not to Gain of Chromosome 8q
To investigate the association between tumour genetics and angiogenesis, the status of chromosome
3, chromosome 8q and the expression of the BAP1 protein were determined in 43 patients. Tumours
with monosomy 3 (n = 21) had a higher MVD compared to tumours with disomy 3 (n = 22, p = 0.008).
Similarly, BAP1-negative tumours (n = 23) had a higher MVD compared to BAP1-positive tumours
(n = 20, p = 0.004) (Figures 2a and 3a). To investigate the role of BAP1 independently of chromosome
3 status, we analysed the association between BAP1 and MVD within groups of disomy 3 and
monosomy 3 tumours separately. Within the group of disomy 3 tumours (n = 22), BAP1 loss (n = 6)
was still related to a higher MVD compared to tumours that expressed BAP1 (n = 16, p = 0.008). Within
the group of monosomy 3 tumours (n = 21), this association could not be established, but that may be
due to a small sample size as only four out of 21 tumours with monosomy 3 had not lost their BAP1
expression (Figure 3b). For further comparisons, we focussed on BAP1 expression.
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lesions. Loss of BAP1 expression was associated with an increased expression of HIF1a and ANGPT2, 
and a decreased expression of VEGF-B, and VHL (all p < 0.05). When looking at vascular markers and 
infiltrate, BAP1 loss was associated with an increased mRNA expression of vascular markers CDH1, 
PECAM1, VWF and infiltrate markers CD3, CD4, CD8 and CD68 (Table S3). 
We corroborated these findings using the TCGA dataset, and found similar results for the 
association between BAP1 loss and increased expression of HIF1a, ANGPT2, CDH1, PECAM1, CD3 
and CD8, and between BAP1 loss and a decreased expression of VHL and VEGF-B. Interestingly, in 
Figure 2. Tumour genetics in relation to MVD and mRNA gen expression. Gain of chr s 8q is
an early event in UM development, while loss of BAP1 is a later event. (a) IHC counts of MVD (n = 43),
(b) mRNA gene expression of CD68 macrophages (n = 54), (c) mRNA gene expression of VEGF-A
(n = 54), (d) mRNA gene expression of VEGF-B (n = 54), (e) mRNA gene expression of HIF1a (n = 54),
and (f) mRNA gene expression of VHL (n = 54). (p-values were obtained using Mann–Whitney U tests,
comparing BAP1+ and n8q with BAP1+ and 8qgain patients, and all BAP1+ with all BAP1− patients.
Abbreviations: BAP1+, BAP1-positive; BAP1−, BAP1-negative; n8q, normal chromosome 8q; 8qgain,
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2.5. Expression of Angiogenesis-Related Genes Is Related to Genetic Progression of UM
Earlier in this study, we noticed that several angiogenesis-related genes are related to the MVD
in UM. We wondered whether the expression of these genes may be related to genetic progression
(early 8q gain and later BAP1 loss) in the 54 cases with data on tumour genetics and mRNA gene
expression (Table S2). First, we compared all BAP1-positive (n = 24) with all BAP1-negative (n = 30)
lesions. Loss of BAP1 expression was associated with an increased expression of HIF1a and ANGPT2,
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and a decreased expression of VEGF-B, and VHL (all p < 0.05). When looking at vascular markers and
infiltrate, BAP1 loss was associated with an increased mRNA expression of vascular markers CDH1,
PECAM1, VWF and infiltrate markers CD3, CD4, CD8 and CD68 (Table S3).
We corroborated these findings using the TCGA dataset, and found similar results for the
association between BAP1 loss and increased expression of HIF1a, ANGPT2, CDH1, PECAM1, CD3
and CD8, and between BAP1 loss and a decreased expression of VHL and VEGF-B. Interestingly, in the
TCGA data, BAP1 loss was also related to an increase of VEGF-A and ANGPT1 (while this was not
observed in the Leiden data) (Table S4).
Second, we evaluated the role of chromosome 8q within the BAP1 expressing tumours. Although
we identified that gain of 8q is not independently related to MVD, a previous study demonstrated that
gain of 8q is related to increased counts of (pro-angiogenic) macrophages [13]. We confirm that within
the group of BAP1-expressing tumours from Leiden, gain of 8q was associated with a higher mRNA
expression of CD3 (lymphocytes, p = 0.026) and especially of more CD68 (macrophages, p = 0.007).
When examining cytokines, within the group of BAP1-expressing tumours, 8q gain was related to an
increased expression of ANGPT2 (p = 0.040) and a decreased expression of VEGF-B (p = 0.022) and
VEGF-C (p = 0.026) (Table S3). The relation between 8q gain, BAP1 loss and the expression of several
of the investigated genes is presented in Figure 2. During tumour progression, VEGF-B and VHL
decrease, while HIF1a increases.
In the TCGA data, gain of 8q was similarly related to an increased expression of CD68 (macrophages),
and expression of PDGF-A, but no relation with any of the other cytokines was observed (Table S4).
3. Discussion
As we already know that genetic events are closely associated with the immunological
microenvironment in UM, including the presence of macrophages and lymphocytes, we analysed
whether genetic events also play a role in the MVD and the expression of angiogenic factors in UM. We
demonstrate an important association between monosomy 3/BAP1 loss and the expression of several
angiogenesis-related genes and MVD. Gain of chromosome 8q was not independently related to MVD,
but it was related to a differential expression of several angiogenesis-related genes: The expression of
pro-angiogenic ANGPT2 was increased, and (presumably) anti-angiogenic VEGF-B was decreased with
8q gain. This may indicate that 8q gain is involved in a preparation phase towards the development of
more vessels. However, it looks as if a true increase in MVD can only be accomplished by a series of
events, in which the BAP1 gene may play an important role. This idea may fit well into the concept of
the angiogenic switch, describing a slow early avascular tumour growth phase, followed by a more
rapid growth with vascular development.
By using mRNA expression techniques, a comprehensive analysis of angiogenesis-related genes
was performed. Interestingly, VEGF-A expression was not related to MVD in our data. VEGF-A is the
main type of VEGF and is considered to be of importance for the development of new blood vessels.
Even more, various studies demonstrated that elevated levels of VEGF-A are present in the aqueous and
vitreous of UM eyes [20–22]. An explanation for our finding could be that VEGF-A is either important
for the most initial development of vasculature, or for the maintenance of previously-developed
vasculature, while other factors influence a further increase in MVD.
Our results show that VEGF-B may have a much more important role in angiogenesis in UM than
previously thought. An abundant expression of VEGF-B was reported earlier in UM cell lines [23], but
the role of VEGF-B has always been described as enigmatic. Interestingly, in our data the expression of
VEGF-B correlated negatively with the MVD. A relation between VEGF-B and MVD is unreported
in UM, but the function of VEGF-B was recently studied in a murine model, using a cutaneous
melanoma cell line. Enforced expression of VEGF-B led to suppressed primary tumour growth in mice
and a reduced MVD, but more metastases [24]. It was proposed that an increase in VEGF-B causes
increased vascular leakiness, a high degree of hypoxia, with increased numbers of tumour-infiltrating
macrophages, leading to a metastasis-promoting environment [24]. Indeed, a relation between high
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mRNA expression of VEGF-B and worse survival was found in patients with lung squamous cell
carcinoma and non-ocular melanoma [24]. Interestingly, the relation between a low VEGF-B expression
and metastasis development in our UM data did not follow the positive correlation that was reported
with other cancers. In the Leiden data, the development of metastasis was not related to VEGF-A
expression, but it related to a decreased expression of VEGF-B. In the TCGA data, both an increased
expression of VEGF-A and a decreased expression of VEGF-B were related to more metastasis formation.
These observations may indicate that the function of VEGF-B regarding tumour behaviour is different
in UM compared to other tumours.
New insights in ischemic signalling pathways have drawn attention to HIF1a-regulated
angiogenesis in UM, and new drugs targeting these pathways are being developed [8]. In our study,
mRNA expression of HIF1a was not significantly related to an increasing MVD (p = 0.089). This may be
due to sample size, as Mouriaux demonstrated a link between HIF1a expression and vascular marker
CD31 in a larger set of 56 UM [25]. A recent study in UM cell lines on HIF1a-related angiogenesis
showed that both VEGF and ANGPTL4 are promotors for tubule formation [26]. The effectors of
HIF1a may therefore include multiple pathways, stressing that not only VEGF-A related pathways may
have relevance. We furthermore demonstrate that BAP1-loss is strongly related to HIF1a expression,
implicating the HIF1a-mediated pathways of angiogenesis in the later steps of UM progression.
However, the exact role of BAP1 in UM development, including angiogenesis, is not well understood.
It can be hypothesized that BAP1 loss leads to an upregulation of HIF1a via the NF-kB cascade, as
BAP1 was shown to suppress this pathway in human oesophageal carcinoma [27], and BAP1 loss
was found to be related to an increased NF-kB expression in UM [28], but the mechanism needs to be
investigated further.
Previously, associations were reported between the MVD and the presence of tumour-associated
macrophages (CD68+ cells [3], and CD68+CD163+ cells [2]). It was hypothesized that macrophages
have a pro-angiogenic effect by, for example, secreting VEGF. We confirm the relationship between
a high MVD and increased counts of CD68+ cells, and also find an association with CD4+ cells.
The numbers of these cells are highly correlated [19]; however, and it has been observed that activated
macrophages can attract a T cell infiltrate [29]. It should; therefore, be further studied if T cells have an
independent relation to vasculature or whether they act downstream of the presence of macrophages.
Regarding tumour size, we identified that LBD (B = 5.15; 95%CI 0.73 to 9.58; p = 0.024), but not
tumour prominence (B = −3.63; 95%CI −9.07 to 1.80; p = 0.18), was related to MVD in a univariate
linear regression analysis. Adjusting for BAP1 status, there was still a trend that LBD related to MVD
(B = 4.16; 95%CI −0.10 to 8.42; p = 0.055) while BAP1 status related to MVD as well (B = −29.08; 95%CI
−53.01 to −5.14; p = 0.019). Makitie detected a weak correlation between MVD and increasing LBD as
well as with prominence, but had a larger study group of 134 UM, and he did not know the BAP1
status [3]. Our results may imply that tumour size alone (with presumed increased hypoxia) is not
the driver of angiogenesis, and that genetics are an important determinant. It would be interesting
to investigate whether increased vascularity explains why some large, yet disomy 3/BAP1-positive
tumours become metastatic. However, our numbers were not sufficient to examine this relation.
Opposed to the relations we identified between tumour genetics and MVD, the presence of
extravascular matrix patterns demonstrated a slightly different relationship. As with MVD, the
status of chromosome 8q was not related to the presence of loops (p = 0.89) or networks (p = 0.32).
However, cases with monosomy 3 demonstrated more often loops (p = 0.038) and networks (p = 0.016).
This finding is line with the earlier observation of Onken et al. that the presence of loops and networks
relates to gene expression profile class II UM [30]. Interestingly, loops and networks did not relate to
BAP1 status (p = 0.13 and p = 0.13, respectively). This finding may underline the different aetiology of
the vascular structures, though we cannot but speculate on the role of BAP1 in this finding.
A limitation of this study was that mainly larger tumours were included as all samples were
obtained from enucleated eyes. This also limited the variation in tumour size. It can be expected that
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new vasculature is especially important for larger lesions; however, so it may be of no major concern
that few small-sized tumours were studied.
While the presence of intra-tumoural vessels and infiltrate was analysed with immunohistochemistry
(IHC) and IF, respectively, the expression of the various angiogenic factors was analysed using mRNA.
This is a well-established technique capable of identifying pathways of interest. However, there may be
differences between mRNA gene expression and protein production. Future studies could investigate
how our findings, which we corroborated using the mRNA expression data of the TCGA project, relate to
data on protein expression of the respective factors.
Our study implicates that angiogenesis should be studied together with the genetic background
of UM. An important future project could be to study if anti-angiogenic treatment is more effective
in specific (genetic) sub groups of UM. As we show that vascularity is related to genetics, it may be
that mainly highly-vascularized lesions are effectively attacked with those treatments or that genetic
profiling can predict responses to anti-angiogenic therapy. Another project may be to study which
other genes on chromosome 3, besides BAP1, are important for MVD development. In this, it may be
important to consider the role of VHL as the VHL gene is, like BAP1, located on chromosome 3. As we
demonstrate a role for VEGF-B in UM angiogenesis, the exact role of this cytokine and the relevance
for anti-angiogenic therapy should be investigated.
4. Materials and Methods
4.1. Patient Selection
Tumour samples were obtained from eyes with UM that had been primarily enucleated at the
Leiden University Medical Center (LUMC, Leiden, The Netherlands) between 1999 and 2008. Clinical
data was retrieved from patient medical files. Survival data was complemented with data from
the Dutch national cancer registry (RANK). The study was approved by the Biobank Committee
of the LUMC (19.060.CBO/uveamelanoomlab-2019-1), and adhered to the tenets of the Declaration
of Helsinki.
The current study includes a previously reported set of 43 tumours with data on MVD, tumour
infiltrate and tumour genetics (Table 1) [2,19], and an additional (partially overlapping) set of 54 tumours
with data on mRNA gene expression and tumour genetics (Table S2). Of all patients, 28 cases with
combined data on MVD and mRNA gene expression were available (Table S1). Clinical data and
survival data of all patients were updated until 1 March 2017.
4.2. Histopathology
Tumour material was snap frozen using 2-methyl butane and later used for DNA and RNA
isolation. Remaining tumour material was fixed in 4% neutral-buffered formalin for 48 h and embedded
in paraffin. Haematoxylin/eosin-stained 4 µm sections were reviewed by an ocular pathologist for
confirmation of the diagnosis and evaluated for histologic parameters (LBD, prominence, cell type,
pigmentation). The eighth edition of the AJCC staging manual was used for tumour classification [31].
4.3. Immunohistochemistry and Immunofluorescence
MVD was assessed in 43 cases with IHC for CD34 as described previously [3]. Counts were
represented as vessels/mm2. Numbers of lymphocytes and macrophages were assessed as described
previously [2,19]. T cells were detected with IF using antibodies against CD3, CD4, CD8 and FoxP3.
Counts were represented as number of cells/mm2. Macrophages were detected with IF using antibodies
against CD68, CD163, and CD68CD163 double-staining. Counts were determined in pixels/mm2.
BAP1 status was assessed with IHC as described previously [32]. Nuclear BAP1 staining was scored by
an experienced ocular pathologist, and categorized as BAP1-positive or BAP1-negative. Extravascular
networks were identified with PAS staining; closed vascular structures were named “loops”, and at
least 3 adjacent loops were named “networks”.
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4.4. Chromosome 3/8q Status and Gene Expression
The QIAmp DNA Mini Kit was used to isolate DNA for single nucleotide polymorphism (SNP)
analysis according to guidelines of the manufacturer (Qiagen, Venlo, The Netherlands). Status of
chromosome 3 was determined with SNP analysis performed with the Affymetrix 250K_NSP chip and the
Affymetrix Cytoscan HD chip (Affymetrix, Santa Clara, CA, USA) [14]. The copy number of chromosome
8q was identified with ddPCR. A threshold of >2.1 was defined as gain of 8q [14]. The RNeasy Mini
Kit was used to isolate mRNA for gene expression analysis (Qiagen, Venlo, The Netherlands). Gene
expression levels were obtained using the Illumina HT-12 v4 chip (Illumina, San Diego, CA, USA).
Angiogenesis-related factors were selected based on literature regarding angiogenesis. Only these
predefined genes were assessed in the current analysis (Table S5).
4.5. TCGA Data
Findings were corroborated using mRNA data from 80 UM patients from the TCGA project:
http://cancergenome.nih.gov/ [33]. In this set, BAP1 expression was provided as mRNA expression
levels, and dichotomized into BAP1-positive and BAP1-negative tumours, using the median [13].
4.6. Statistical Analysis
Analyses were performed using SPSS version 23 (I.B.M.). Categorical data was analysed with
Chi-square tests. Numerical data was analysed with the Mann–Whitney U test between 2 groups,
and with the Jonckheere test between multiple groups with a trend. Correlations were assessed
with the Spearman’s test. Linear regression was performed for univariate and multivariate analyses.
Survival data was analysed with the Kaplan–Meier method and log-rank tests; groups of high and
low MVD and mRNA gene expression were based on the median. p-values < 0.05 were considered
statistically significant.
5. Conclusions
In conclusion, we demonstrated that the genetic evolution of UM not only involves tumour
infiltrate, but also tumour angiogenesis. Late events (such as BAP1 loss) are related to an increase in
MVD, while early events (such as 8q gain) are not. Gain of 8q may be related to a preparation phase;
however, as several angiogenesis-related genes are already expressed differentially in the absence of
monosomy 3/BAP1 loss. We observed new associations with MVD, such as with monosomy 3/BAP1
loss, an increased count of lymphocytes, and a decreased expression of VEGF-B, indicating that more
(and other) mechanisms are involved in angiogenesis of UM than previously thought.
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